Celldex Therapeutics, Inc.

Celldex Therapeutics, Inc. is a U.S.-based biopharmaceutical company focused on mast cell biology and immune-modulating antibodies for severe inflammatory, allergic, autoimmune and other hard-to-treat diseases. Its lead asset, barzolvolimab (CDX-0159), is a monoclonal antibody that targets the KIT receptor and is being developed across multiple mast-cell-driven indications, including chronic spontaneous urticaria and atopic dermatitis. The company is also building a next-generation bispecific antibody platform, with CDX-622 as its first bispecific candidate targeting TSLP and SCF. Celldex is still in the clinical-development stage and currently has limited commercial infrastructure, so its value creation depends on successful late-stage trials, regulatory approvals and eventual commercialization or partnering.

−18 381,0 %

87,1 %

−16 748,0 %

−78,0 %

10.49

10.49

— Celldex Therapeutics, Inc.
%
Lead antibody therapeutics70% Clinical-stage monoclonal antibody programs centered on barzolvolimab for mast-cell-driven inflammatory and allergic diseases.
Bispecific antibody platform20% Next-generation bispecific candidates such as CDX-622 designed to address complementary inflammatory pathways.
Collaborative research and licensing revenue10% Revenue from product development agreements, milestone-related payments and related collaboration activities.

Celldex does not sell approved commercial products today; its current counterparties are primarily clinical...

  • Collaborative partners and research sponsorsprimary

    They buy or fund R&D services, development rights and milestone-linked programs to advance antibody candidates.

  • Physicians and specialty clinicsprimary

    They would prescribe barzolvolimab or future products if approved, based on efficacy, safety and convenience in chronic inflammatory disease.

  • Third-party payorsprimary

    They influence access and uptake through reimbursement decisions for high-cost biologic therapies.

  • Patients with mast-cell-driven diseasesprimary

    They are the end users of the therapy, seeking better control of symptoms where current treatments are inadequate.

  • Specialty distributors and pharmaciessecondary

    They would handle fulfillment and distribution for any commercial biologic launch.

Celldex is headquartered in the United States and its development, regulatory and commercial planning is centered there...

  • •Headquartered in the United States
  • •Clinical development and FDA-facing work are primarily U.S.-based
  • •Future commercialization could expand internationally if approved
  • •Manufacturing is supported through commercial CMOs for late-stage supply
  • •No country-level revenue concentration was disclosed in the excerpts
  • •Geographic exposure is mainly regulatory and operational rather than sales-driven

Celldex’s strategy is to convert its mast-cell biology platform into a commercial-stage immunology company by advancing...

01
Complete late-stage barzolvolimab developmentshort-term

Barzolvolimab is the company’s lead value driver and the main path to a commercial product.

02
Build launch-ready manufacturing capabilityshort-term

Commercial success requires reliable drug substance and drug product supply before approval.

03
Broaden the pipeline with bispecific antibodiesmedium-term

A second platform can reduce single-asset dependence and extend growth beyond barzolvolimab.

04
Retain strategic flexibility on commercializationmedium-term

The company currently lacks a full commercial organization and may need partners or a build-out.

Celldex is exposed to the classic risks of a clinical-stage biotech: it has no product revenue today, depends on...

critical

Clinical development failure

Barzolvolimab and CDX-622 are still in development, and late-stage trials may not confirm efficacy or safety.

Scope
Lead asset value
Materiality
high
high

Need for additional capital

The company currently has no product revenue and must fund expensive clinical development and manufacturing scale-up.

Scope
Corporate liquidity and program continuity
Materiality
high
high

Regulatory approval uncertainty

Approval depends on FDA and potentially foreign regulators, which can require additional data or delay launches.

Scope
Time to market
Materiality
high
high

Commercialization and reimbursement risk

The company lacks a full commercial organization and future uptake will depend on payor coverage and physician adoption.

Scope
Future revenue realization
Materiality
high
medium

Third-party manufacturing dependence

Late-stage and potential commercial supply rely on contract manufacturers and successful process qualification.

Scope
Supply continuity
Materiality
medium
medium

Intellectual property and licensing risk

Barzolvolimab is licensed from Yale and future economics depend on patent and license terms.

Scope
Royalty burden and exclusivity
Materiality
medium
Revenue recognition for collaboration agreements
Can create volatile quarterly revenue and cumulative catch-up adjustments
Contingent consideration
May affect operating results and balance-sheet liabilities
R&D expense allocation
Affects interpretation of pipeline priorities and cash burn
Stock-based compensation
Influences reported losses and adjusted performance analysis
Intangible and long-lived asset impairment
Potential non-cash write-downs

CytomX Therapeutics, Inc.

CTMX · Pharmaceutical Preparations

Jasper Therapeutics, Inc.

JSPR · Biological Products, (No Diagnostic Substances)

Immunome Inc.

IMNM · Pharmaceutical Preparations

Barinthus Biotherapeutics plc.

BRNS · Pharmaceutical Preparations

Aldeyra Therapeutics, Inc.

ALDX · Pharmaceutical Preparations

Edesa Biotech, Inc.

EDSA · Pharmaceutical Preparations

: 28/04/2026